ArticleScientific reports2025
METTL3-mediated m6A modification of TACSTD2 mRNA inhibits papillary thyroid cancer progression by activating the TNF signaling and blocking epithelial-mesenchymal transition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A bioinformatics pipeline for identifying clinically relevant immune and adhesion biomarkers in thyroid risk stratification.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Papillary thyroid cancer (PTC) represents a prevalent endocrine neoplasm. Dysregulated tumor-associated calcium signal transducer 2 (TACSTD2) expression is functionally involved in the progression of multiple cancers. Nonetheless, the biological molecular mechanisms underlying TACSTD2 in PTC remain unclear. To verify the biological function of TACSTD2 in PTC, we conducted loss- and gain-of-function experiments, namely, cell proliferation (Cell Counting Kit-8), EdU incorporation, colony formation, and transwell migration/invasion assays, along with establishing a nude mouse xenograft tumor model. Our findings revealed that TACSTD2 knockout impeded PTC cell proliferation, migration, and invasion in vitro and reduced tumorigenicity in vivo. In contrast, TACSTD2 overexpression reversed these effects in vitro. Through integrated bioinformatics analysis and experimental validation, TACSTD2 was recognized as a downstream target of methyltransferase-like 3 (METTL3)-modulated N6-methyladenosine (m6A) modification. In an m6A-dependent manner, METTL3 reduced TACSTD2 mRNA stability. m6A-mediated degradation of TACSTD2 mRNA was reliant on the m6A reader protein YTHDC2. As evidenced by rescue experiments, TACSTD2 overexpression resulted in a partial restoration of the METTL3-induced tumor-suppressive phenotype. Finally, the METTL3/TACSTD2/YTHDC2 axis was confirmed to be an inhibitor in PTC and activates the TNF signaling to promote cell apoptosis and inhibit the epithelial-mesenchymal transition. Collectively, METTL3-modulated m6A modification of TACSTD2 exerts an indispensable tumor-suppressive function in PTC progression. The METTL3/TACSTD2/YTHDC2 axis may serve as a molecular target for PTC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.